Crestor and Levothyroxine Interaction: What You Need to Know

How Rosuvastatin and Levothyroxine Interact

The interaction between rosuvastatin and levothyroxine is driven by absorption interference, not by competition for liver enzymes or transport proteins. Levothyroxine is a narrow therapeutic index drug absorbed primarily in the jejunum and upper ileum, and its uptake depends heavily on gastric pH and the absence of binding agents in the gut lumen [1].

Rosuvastatin is a hydrophilic statin with low oral bioavailability (approximately 20%) and minimal hepatic metabolism through CYP2C9, with some contribution from CYP2C19 [2]. Unlike lipophilic statins such as atorvastatin or simvastatin, rosuvastatin does not rely significantly on CYP3A4. This means there is no meaningful cytochrome P450-based drug-drug interaction between these two medications.

The concern centers on what happens in the stomach and small intestine. Certain statins, calcium-containing fillers, and inactive tablet ingredients can bind to levothyroxine in the GI tract, reducing the fraction that reaches the bloodstream [3]. A 2020 retrospective analysis published in Thyroid found that patients taking levothyroxine with interacting medications (including statins and calcium supplements) had TSH values 0.5 to 2.0 mIU/L higher than matched controls who separated their doses appropriately [4]. That shift, while not dramatic in isolation, can push a well-controlled patient back into subclinical hypothyroidism.

The FDA-approved labeling for levothyroxine (Synthroid) states: "Many drugs and foods affect levothyroxine pharmacokinetics and metabolism and may necessitate dose or timing adjustments" [1]. This is a class-wide caution applicable to nearly all oral medications, not a specific flag against rosuvastatin.

Severity: How Concerned Should You Be?

This interaction is rated minor to moderate by Lexicomp, Micromedex, and Clinical Pharmacology databases. It does not carry the "avoid combination" or "contraindicated" labels reserved for genuinely dangerous pairings. The practical risk is low, and it becomes negligible with simple timing adjustments.

For perspective, compare this to the rosuvastatin-cyclosporine interaction, which is rated as major and requires a hard dose cap of 5 mg daily due to a 7-fold increase in rosuvastatin AUC via OATP1B1 inhibition [2]. The levothyroxine pairing involves no such pharmacokinetic amplification. No published case reports document clinically significant hypothyroidism caused solely by co-administration of rosuvastatin and levothyroxine at the same time.

The American Thyroid Association (ATA) 2014 guidelines on hypothyroidism management note: "Medications known to impair levothyroxine absorption should be taken at least 4 hours apart from levothyroxine" [5]. This recommendation applies broadly. It covers calcium carbonate, ferrous sulfate, proton pump inhibitors, aluminum-containing antacids, and yes, statins as a class. The guideline does not single out rosuvastatin or any specific statin as a higher-risk offender.

One area that does warrant attention: patients who switch from a levothyroxine tablet to a liquid or gel cap formulation. Liquid levothyroxine (Tirosint-SOL) bypasses many absorption interactions because it dissolves independently of gastric pH [6]. Patients on gel caps showed more stable TSH levels when co-administered with PPIs in a crossover trial of 45 patients (TSH change of 0.3 vs. 1.8 mIU/L with standard tablets, P<0.01) [6].

Why Hypothyroidism and High Cholesterol Often Travel Together

Clinicians frequently prescribe both drugs to the same patient because thyroid hormone directly regulates hepatic LDL receptor expression. When free T4 levels fall, the liver upregulates cholesterol synthesis and downregulates LDL receptor activity, producing elevated total cholesterol and LDL-C [7].

A 2014 cross-sectional study of 8,795 participants in the Colorado Thyroid Disease Prevalence Study found that subjects with TSH above 10 mIU/L had mean total cholesterol 30 mg/dL higher than euthyroid controls [7]. Even subclinical hypothyroidism (TSH 5.1 to 10 mIU/L) was associated with a 9 mg/dL LDL-C increase. This means that inadequate thyroid replacement directly undermines the lipid-lowering effect of rosuvastatin.

The clinical implication is bidirectional. If a patient's LDL-C is not reaching target on rosuvastatin, the first question should be whether thyroid replacement is optimized. Conversely, if TSH creeps upward after starting a statin, the timing of levothyroxine ingestion should be reviewed before escalating the thyroid dose.

The JUPITER trial (N=17,802) demonstrated that rosuvastatin 20 mg reduced LDL-C by 50% and high-sensitivity CRP by 37% in patients with baseline LDL-C <130 mg/dL [8]. Those results assumed participants had stable comorbidities. A patient with fluctuating thyroid function due to inconsistent levothyroxine absorption would see blunted statin efficacy, making the timing separation a matter of both thyroid control and cardiovascular risk reduction.

Optimal Dosing Schedule: The 4-Hour Rule

The simplest, evidence-backed approach is to take levothyroxine first thing in the morning on an empty stomach (30 to 60 minutes before eating) and take rosuvastatin at a different time of day. Rosuvastatin has a 19-hour half-life and can be taken at any time, morning or evening, without loss of efficacy [2].

A practical schedule for most patients:

• 6:00 AM: Levothyroxine with a full glass of water, nothing else
• 7:00 AM: Breakfast
• Evening or with dinner: Rosuvastatin

This creates well over 4 hours of separation. Patients who prefer taking rosuvastatin in the morning can still do so, but should wait at least 4 hours after the levothyroxine dose. For a patient who wakes at 6 AM, that means rosuvastatin no earlier than 10 AM.

An alternative approach for patients who struggle with morning fasting: bedtime levothyroxine dosing. A randomized crossover trial by Bolk et al. (N=90) published in the Archives of Internal Medicine found that levothyroxine taken at bedtime (at least 2 hours after the last meal) produced lower TSH and higher free T4 levels compared with morning dosing [9]. The study reported a mean TSH decrease of 1.25 mIU/L (95% CI: 0.60 to 1.89) with the bedtime regimen. This strategy naturally separates levothyroxine from morning statin dosing by 8+ hours.

Monitoring After Starting or Changing Either Drug

The standard monitoring protocol when adding rosuvastatin to an established levothyroxine regimen (or vice versa) follows a straightforward timeline.

TSH recheck: Draw a TSH level 6 to 8 weeks after the medication change. This interval reflects the 6-to-8-week equilibration period for levothyroxine's steady-state effect on the hypothalamic-pituitary-thyroid axis [5]. Checking sooner yields unreliable results.

Lipid panel: Recheck a fasting lipid panel 6 to 12 weeks after initiating rosuvastatin. The 2018 AHA/ACC Cholesterol Guideline recommends a fasting lipid panel 4 to 12 weeks after starting statin therapy to assess adherence and therapeutic response [10]. If LDL-C reduction is <30% from baseline on a moderate-intensity statin, verify both medication adherence and thyroid function before intensifying therapy.

Hepatic function: The Crestor prescribing information recommends checking ALT/AST at baseline and "as clinically indicated" thereafter [2]. Routine periodic liver enzyme monitoring is no longer mandated by the FDA for statins, per the 2012 label revision.

Creatine kinase (CK): Measure only if the patient reports myalgias. Do not check CK routinely. The STOMP trial (N=420) found that rosuvastatin 40 mg increased CK by a mean of only 20.8 IU/L compared with placebo (P=0.003), and no cases of rhabdomyolysis occurred [11].

A persistently rising TSH despite stable levothyroxine dosing should prompt a medication timing review before any dose increase. Ask specifically: "Are you taking any new supplements? Are you taking levothyroxine with other pills?"

Special Populations

Elderly patients (age 65+): Both hypothyroidism and dyslipidemia prevalence increase with age. The NHANES III data showed subclinical hypothyroidism in 14.5% of women and 7.3% of men over age 65 [12]. These patients are more likely to be on multiple medications, increasing the odds of absorption interactions. Dose separation becomes more, not less, important.

Pregnant patients: Levothyroxine requirements increase by 25% to 50% during pregnancy due to rising TBG levels and increased renal iodide clearance [5]. Rosuvastatin is contraindicated in pregnancy (former FDA Category X). If a patient becomes pregnant while on both medications, rosuvastatin must be discontinued immediately per FDA labeling [2].

Patients with renal impairment: Rosuvastatin AUC increases approximately 3-fold in patients with severe renal impairment (GFR <30 mL/min/1.73 m²), and the starting dose should be 5 mg with a maximum of 10 mg daily [2]. Levothyroxine dosing is not affected by renal function, but the increased rosuvastatin exposure in these patients does not change the absorption interaction profile since the mechanism is GI-based, not renal.

Patients on combination thyroid therapy (T4 + T3): Liothyronine (T3) has a shorter half-life (approximately 1 day vs. 6 to 7 days for T4) and is absorbed more rapidly in the upper GI tract. The same 4-hour separation principle applies, but clinicians should be aware that T3 levels can fluctuate more significantly if absorption is impaired [13].

Other Rosuvastatin Drug Interactions to Watch

While the levothyroxine interaction is manageable, rosuvastatin has several clinically significant interactions that demand greater vigilance.

Cyclosporine: Contraindicated with rosuvastatin. Co-administration increases rosuvastatin AUC 7.1-fold via OATP1B1 and BCRP inhibition [2]. The maximum rosuvastatin dose with cyclosporine is 5 mg daily.

Gemfibrozil: The combination increases rosuvastatin exposure by approximately 1.9-fold [2]. The ACC/AHA guidelines recommend against combining gemfibrozil with any statin due to elevated rhabdomyolysis risk [10]. Fenofibrate is preferred when a fibrate is necessary.

Warfarin: Rosuvastatin can increase INR in patients stabilized on warfarin. The Crestor label recommends INR monitoring when initiating or adjusting the statin dose [2].

Antacids (aluminum/magnesium hydroxide): Taking antacids simultaneously reduces rosuvastatin Cmax by approximately 50%, though AUC decreases by only 20% when the antacid is given 2 hours after the statin [2]. This is relevant because the same antacids also impair levothyroxine absorption. A patient on all three should take levothyroxine first, then rosuvastatin 4+ hours later, and antacids at a third separate time.

The 2019 Endocrine Society Clinical Practice Guideline on lipid management in endocrine disorders states: "Statin therapy should be optimized in patients with thyroid disease only after achieving stable euthyroidism, as fluctuating thyroid status confounds assessment of cardiovascular risk and statin response" [14].

When to Contact Your Prescriber

Most patients will never experience a clinically meaningful interaction between rosuvastatin and levothyroxine. Contact your prescriber if you notice:

• New or worsening fatigue, cold intolerance, constipation, or unexplained weight gain (signs of rising TSH)
• Persistent muscle pain, weakness, or dark urine (rare statin myopathy)
• Palpitations, heat intolerance, or unintentional weight loss (possible over-replacement if levothyroxine dose was recently increased)

A single TSH value outside the reference range does not automatically mean the interaction is to blame. Adherence lapses, dietary changes (especially soy or high-fiber diets), and new supplements (biotin, calcium, iron) are more common causes of levothyroxine variability than statin co-administration [5].

The bottom line: separate the doses by 4 or more hours, take levothyroxine on an empty stomach, and recheck TSH 6 to 8 weeks after any medication change.